StockTake: ReNerve banks $3.2M to ramp US sales and nerve-repair product rollout

Host Tylah Tully looks at ReNerve’s (ASX:RNV) latest capital raise, which saw $3.2 million from new and existing, and institutional and sophisticated investors land in its pockets. 

The funds will be used to fuel the company’s revenue-generating ranges including NervAlign, EmpliQ, its amniotic tissue ranges and a nerve-conduit line set for launch as the next growth catalyst.

Watch the video for more.

This video was developed in collaboration with ReNerve, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.